Vincent graduated with a MSc degree in Medical Biology from the University of Amsterdam, where he also obtained a PhD in Biochemistry. His doctoral research focused on the phospholipid flippase ATP8B1 and its role in intracellular trafficking. This work resulted in three first-authored experimental publications in highly-ranked scientific journals.
Following this Vincent continued to work in academia as a post-doctoral researcher in the Academic Medical Center in Amsterdam. Using direct input from the pharmaceutical industry he developed and studied several cell culture systems that can act as models for drug metabolism and toxicity testing. He also became the main inventor on a patent application for a new improved liver cell line with potential use in a bio-artificial liver system.
Vincent went on to work as an analyst in the Healthcare team of M Ventures, the corporate venture capital arm of Merck KGaA, where he performed due diligence on technical, commercial and patented features of new investment proposals in the fields of (immuno-)oncology and immunology.
Prior to joining HGF, Vincent worked in the technology transfer office of the University of Leiden, specifically at the Leiden University Medical Center. Here, his roles included scouting for new (patentable) inventions, IP management, business development, advising on start-ups and investments, licencing and research agreements. During this time he came into contact with many cutting-edge technologies in the field of medical devices, diagnostic methods, software applications, antibodies, and cancer neoepitopes.
At HGF Vincent gained ample experience with patenting agrochemicals and various other subjects that combine chemistry and biology.
With news that the Austrian parliament has ratified the Protocol on the provisional application of the Agreement on a Unified Patent Court on 2 December 2021, the Unified Patent Court …Read article
One of the most often asked questions of patent attorneys is “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is …Read article
When deciding whether to invest in a company, an investor will inevitably have to decide the value of the company. Taking a simplified view, a company’s valuation can be considered …Read article
Strategies for navigating European patent portfolios in healthcare. Securing patent protection is critically important for innovative companies operating in the healthcare sector. European patent filings in healthcare, and particularly those …Read article
Using SleepCogni as a case study, we look at some key ways that IP can help start-ups to develop their technology and secure investment. SleepCogni is a SleepTech start-up who …Read article
The University of Hong Kong is hosting a webinar on ‘IP Management: AI and 5G in healthcare’ on 9th December 2021 with HGF’s Partner Dr Chris Benson and Patent Director …Event details
Join our webinar on 1st December, where speakers from Shiga, one of the leading IP firms in Japan, will present on ‘Patent eligibility of AI-related pharmaceutical inventions and practical tips …Event details
It is now eight years since the first lab-grown burger was unveiled by a team of scientists at Maastricht University, but since then the path to market has been slow. …Read article
If you would like to discuss how HGF could help you, contact one of our IP specialists.